Investigational Drug Details
| Drug ID: | D361 |
| Drug Name: | Teneligliptin |
| Synonyms: | Teneligliptin |
| Type: | Chemical drug |
| DrugBank ID: | DB11950 |
| DrugBank Description: | Teneligliptin has been investigated for the treatment of Type 2 Diabetes Mellitus. |
| PubChem ID: | 11949652 |
| CasNo: | 760937-92-6 |
| Repositioning for NAFLD: | No |
| SMILES: | Cc1cc(n(n1)c1ccccc1)N1CCN(CC1)[C@H]1C[C@H](NC1)C(=O)N1CCSC1 |
| Structure: |
|
| InChiKey: | WGRQANOPCQRCME-PMACEKPBSA-N |
| Molecular Weight: | 426.59 |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | DPP4 inhibitor |
| Therapeutic Category: | -- |
| Clinical Trial Progress: | Clinical trial on-going (JPRN-UMIN000013048) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0906 | JPRN-UMIN000013048 | Not applicable | Not Recruiting | No Results Available | 03/02/2014 | 2 April 2019 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A03745 | 33879970 | J Clin Biochem Nutr | Comparison of dapagliflozin and teneligliptin in nonalcoholic fatty liver disease patients without type 2 diabetes mellitus: a prospective randomized study. | Details |
| A05650 | 33173107 | Sci Rep | Dipeptidyl peptidase-4 inhibitor protects against non-alcoholic steatohepatitis in mice by targeting TRAIL receptor-mediated lipoapoptosis via modulating hepatic dipeptidyl peptidase-4 expression. | Details |
| A08104 | 32245205 | Int J Mol Sci | Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis. | Details |
| A16659 | 28260070 | Int J Mol Med | A long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, as a preventive drug for the development of hepatic steatosis in high-fructose diet-fed ob/ob mice. | Details |
| A19257 | 26670228 | Int J Mol Sci | The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice. | Details |
| A19921 | 26264980 | J Endocrinol | Teneligliptin improves metabolic abnormalities in a mouse model of postmenopausal obesity. | Details |
| A23630 | 23613622 | World J Gastroenterol | Dipeptidyl peptidase-4: a key player in chronic liver disease. | Details |